Since 1999, Vitreo-Retinal Associates has conducted more than 50 clinical research trials in an effort to provide our patients with cutting edge treatments for retinal diseases. These programs allow our patients access to the most up-to-date treatments and medications not yet available to the general public. VRA’s physicians and full time research staff are proud to be the area’s leader in innovative eye research.
Did you know that VRA played a role in the discovery of drugs used to treat wet macular degeneration? Every week we perform hundreds of injections of Avastin, Lucentis, and Eylea for macular degeneration, but there was a time when these drugs did not exist! With the help of our patient volunteers, VRA has participated in several of the studies which are required by the FDA in order to gain approval for medications like Lucentis and Eylea!
New studies with cutting-edge treatments for our patients’ retinal diseases are always on the horizon!
Current Clinical Research Trials
- Investigator Initiated Protocol SM09-0626-01 Lipid and Cytokine Analysis of Vitreous Samples from Clinically Indicated Vitrectomies
- Genentech-Roche Ltd GR40398 RHINE Study of RO6867461 in patients with Diabetic Macular Edema
- Chengdu Kanghong Panda 2: Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular Age-Related Macular Degeneration
- Genentech, Inc GR40973 GAllego study of R07171009 in patients with Geographic Atrophy secondary to Age-Related Macular Degeneration
- RHONE-X: A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema (Rhone-X)
- DRCR Protocol AF: Fenofibrate for Prevention of Diabetic Retinopathy Worsening
Past Clinical Research Trials
- Allergan Dexamethasone Posterior Segment Drug Delivery System for DME
- Alimera Iluvien Implant for DME
- ThromboGenics Microplasmin for Vitreo-Macular Traction
- Lpath iSONEP for ARMD
- Regeneron VEGF-Trap for ARMD
- Genentech Lucentis for CRVO
- Genentech Lucentis for CRVO Ext.
- Novartis Aliskiren for DME
- GSK oral Pazopanib for ARMD
- GSK topical Pazopanib for ARMD
- GSK topical Pazopanib for ARMD Ext.
- Novartis Visudyne/Lucentis for ARMD
- Lilly Ruboxistaurin for DME
- Lilly Ruboxistaurin for DME Ext.
- Genentech Lucentis for ARMD
- Alcon Anecortave Acetate for wet ARMD
- Novartis Visudyne/Triamcinolone/Macugen for ARMD
- Genaera Squalamine for ARMD
- Alcon Anecortave Acetate for dry ARMD
- Lilly Ruboxistaurin for center threatening DME
- DRCR laser photocoagulation for DME
- Alcon Anecortave Acetate/Visudyne for ARMD
- Ciba/Novartis PKC412 for DME
- Vitrase for vitreous hemorrhage
- Santen 32-007 study of intravitreal Sirolimus for posterior uveitis
- Glaxo Smith Kline MD 7114987 study of topical Pazopanib for wet macular degeneration
- DRCR Protocol R study of topical NSAID for non-central diabetic macular edema
- Diabetic Clinical Research Network (DRCR) Protocol N study of intravitreal Lucentis for diabetic vitreous hemorrhage
- Regeneron VGFT-OD-0819 study of intravitreal VEGF-Trap for central retinal vein occlusion
- Alcon C-10-083 study of intravitreal ESBA 1008 for wet macular degeneration
- Regeneron VGFT-OD-0910 extension study of intravitreal VEGF-Trap for wet macular degeneration
- Alimera C-01-11-008 extension study of intravitreal Iluvien for diabetic macular edema
- Investigator Initiated Protocol VARI 2011 002 Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for diabetic macular edema and exudative macular degeneration
- Allergan 206207-024 Comparison of Dexamethasone Posterior Segment Drug Delivery System to Ranibizumab in patients with diabetic macular edema
- Regeneron VGFT e-RVO-1027 VEGF Trap-Eye in patients with macular edema secondary to branch retinal vein occlusion
- iDEAL 2010-007-03-DME study7 of iCo-007 for diabetic macular edema
- Alcon C-12-006 Study of ESBA1008 vs. Eylea for treatment naive wet macular degeneration
- Alcon C-12-074 Study of CLG561 for advanced macular degeneration
- Novartis CLFG316A2203 study of intravitreal LFG316 for geographic atrophy in dry macular degeneration.
- DRCR Protocol T study of Aflibrcept, Bevacizumab, and Ranibizumab for diabetic macular edema
- Allergan 150998-004 Evaluation of Abicipar Pegol in patients with decreased vision due to diabetic macular edema
- Alcon LHA510-2201 study for topical LHA510 in patients with wet macular degeneration
- DRCR Protocol V treatment for DME in eyes with very good VA
- Video describing the DRCR Protocol V
- Roche Study of Lampalizumab for geographic atrophy in dry macular degeneration (website)
- Alcon RTH258-C001 Study of RTH258 vs. Aflibercept for treatment naive wet macular degeneration
- Ohr-1601 study of topical Squalamine for wet macular degeneration
- DRCR Protocol W: Intravitreous anti-VEGF treatment for the prevention of vision threatening diabetic retinopathy in eyes at high risk
- Regeneron R910-3-DME-1518 study of R910 vs. Aflibercept for diabetic macular edema
- Graybug Vision Altissimo Study: A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration
- DRCR Protocol AC: Aflibercept vs. Bevacizumab + Deferred Aflibercept for the treatment of Diabetic Macular Edema
- Novartis Pharmaceuticals: Study of Efficacy ansd Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
- SCD411-CP101: A Phase III Randomized, Double-Masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity Between SCD411 and Eylea® in Subjects With Neovascular Age-related Macular Degeneration
To Learn More About Our Clinical Research Trials, Please Contact:
Carla Smith, Clinical Research Coordinator
Vitreo-Retinal Associates
2505 E Paris Ave, SE
Suite 100
Grand Rapids, MI 49546
